Rift Valley fever virus (RVFV) is a zoonotic arbovirus of the Phenuiviridae family. Infection causes abortions in pregnant animals, high mortality in neonate animals, and mild to severe symptoms in both people and animals. There is currently an ongoing effort to produce safe and efficacious veterinary vaccines against RVFV in livestock to protect against both primary infection in animals and zoonotic infections in people. To test the efficacy of these vaccines, it is essential to have a reliable challenge model in relevant target species, including ruminants. We evaluated two goat breeds (Nubian and LaMancha), three routes of inoculation (intranasal, mosquito-primed subcutaneous, and subcutaneous) using an infectious dose of 10⁷ pfu/mL, a virus strain from the 2006⁻2007 Kenyan/Sudan outbreak and compared the effect of using virus stocks produced in either mammalian or mosquito cells. Our results demonstrated that the highest and longest viremia titers were achieved in Nubian goats. The Nubian breed was also efficient at producing clinical signs, consistent viremia (peak viremia: 1.2 × 10³⁻1.0 × 10⁵ pfu/mL serum), nasal and oral shedding of viral RNA (1.5 × 10¹⁻8 × 10⁶ genome copies/swab), a systemic infection of tissues, and robust antibody responses regardless of the inoculation route. The Nubian goat breed and a needle-free intranasal inoculation technique could both be utilized in future vaccine and challenge studies. These studies are important for preventing the spread and outbreak of zoonotic viruses like RVFV and are supported by the Canadian-led BSL4ZNet network.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316315PMC
http://dx.doi.org/10.3390/v10120709DOI Listing

Publication Analysis

Top Keywords

routes inoculation
8
rvfv
4
rvfv infection
4
infection goats
4
goats routes
4
inoculation
4
inoculation rift
4
rift valley
4
valley fever
4
fever virus
4

Similar Publications

The objective of this study was to evaluate the effects of the vaccine administration route and the concurrent use of injectable trace minerals (ITM) with booster vaccination on the circulating leukocyte counts and T cell subpopulations in dairy calves challenged with Bovine viral diarrhea virus 2 (BVDV2) and Bovine herpes virus 1 (BHV1). A total of 60 Holstein male calves were used in this study. Forty-eight calves were administered a MLV intranasal (IN) vaccine containing BHV1, BRSV, BPI3V (Inforce 3®), and randomly assigned to subcutaneous (SC) administration of injectable trace minerals (ITM, n = 24) or saline (SAL, n = 24).

View Article and Find Full Text PDF

Enterovirus A71 (EV-A71) has caused hand, foot, and mouth disease with an increased prevalence of neurological complications and acute mortality, threatening young children around the globe. By provoking mucosal immunity, intranasal vaccination has been suggested to prevent EV-A71 infection. However, antigens delivered via the nasal route usually fail to induce a protective memory response.

View Article and Find Full Text PDF

The Zika virus (ZIKV) epidemic elicited a rapid commitment to the development of animal models for ZIKV research. Non-human primates (NHPs) and mice have made significant contributions to this research, but NHPs are expensive, have a long gestation period, and are available only in small numbers; non-genetically modified mice are resistant to infection. To address these deficiencies, we have established the laboratory opossum, , as a small animal model that complements the mouse and monkey models.

View Article and Find Full Text PDF

The development of effective and safe vaccines and their timely delivery to the public play a crucial role in preventing and managing infectious diseases. Many vaccines have been produced and distributed globally to prevent COVID-19 infection. However, establishing effective vaccine development platforms and evaluating their safety and immunogenicity remains critical to increasing health security, especially in developing countries.

View Article and Find Full Text PDF

CRISPR/Cas9 Eye Drop HSV-1 Treatment Reduces Brain Viral Load: A Novel Application to Prevent Neuronal Damage.

Pathogens

December 2024

Laboratório de Virologia e Parasitologia Molecular, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro 21040900, RJ, Brazil.

Herpes simplex virus-1 (HSV-1) can invade the central nervous system (CNS). However, antiviral drugs used to treat HSV-1 have significant toxicity and resistance. An alternative approach involves the use of the CRISPR/Cas9 complex as a viral replication inhibitor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!